September 23, 2021

FDA authorizes Pfizer-BioNTech COVID-19 vaccine boosters for certain populations

By: Judy Mathias

Editor's Note

The Food and Drug Administration (FDA) on September 22 amended the emergency use authorization (EUA) for Pfizer-BioNTech’s COVID-19 vaccine to allow for use of a single booster to be administered at least 6 months after completion of the primary series in those:

  • 65 years of age and older
  • 18 through 64 years of age at high risk of severe COVID-19
  • 18 through 64 years of age whose frequent institutional or occupational exposure to COVID-19 puts them at high risk of serious complications of COVID-19, including severe COVID-19.

Sponsored Message

The authorization applies only to the Pfizer-BioNTech vaccine. 


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat